Success Stories: National Interest Waiver Granted for Clinical Pharmacologist Addressing Health Inequities with Precision Tools
Client’s Testimonial:
“My experience with the Chen Immigration Team on EB2-NIW petition was exceptional. Because of personal priorities, I started the case preparation in 2021, completed all the required documents, and submitted my petition in Dec 2023. During this period, the template for case preparation has improved over time to maximize applicants’ contributions, indicating continuous improvement and dedication from the Chen Immigration Team. The most impressive service, in my opinion, is how responsive the team was. From case preparation to travel advice, I always receive the reply within 1-2 days, which is much more responsive compared to other immigration services that I had interacted with for other reasons. I highly recommend North America Immigration Law Group to those who need support with immigration services.”
On June 3rd, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Clinical Pharmacologist in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Clinical Pharmacologist
Country of Origin: Taiwan
State of Residence at the Time of Filing: California
Approval Notice Date: June 3rd, 2025
Processing Time: 1 year, 5 months, 5 days
Case Summary:
The client’s work began with a fundamental question: why do patients with the same diagnosis respond differently to the same treatment? This question led him to pursue a cross-disciplinary research path at the intersection of biomedical science, pharmacotherapy, and precision medicine. His investigations focus on the complex interactions between drug concentration, pharmacogenes, and the gut microbiome, particularly in the context of cancers, cardiovascular disease, and metabolic disorders.
What sets our client’s research apart is its direct relevance to real-world healthcare outcomes, especially for high-risk and underserved patient populations. By identifying biological markers that influence how individuals metabolize and respond to medications, he is helping pave the way for more personalized and effective treatments.
The value of this work has been recognized through multiple prestigious funding awards, including from the National Institutes of Health (NIH) and its National Center for Advancing Translational Sciences, as well as from the National Science Council of Taiwan and the Executive Yuan of Taiwan. These endorsements reflect both the scientific merit and the global importance of his contributions.
Alongside his funded research, our client has built a robust academic track record:
➢ 16 peer-reviewed journal articles, 7 of them first-authored,
➢ 5 book chapters, demonstrating his role in shaping the broader biomedical discourse,
➢ 126 citations, reflecting a growing impact in the scientific community,
➢ At least 3 formal peer reviews, and
➢ Invitations to serve as a review editor for two academic journals.
“[Client] is working in an area of great national and international importance, as medical developments simultaneously benefit the health of millions of individuals as well as the advancement of several major industries. Considering the merit of his research in conjunction with his publication in selective journals and the recognition of his work across the field, [client] has clearly established himself as a valued leader and irreplaceable asset in biomedical science.”
To secure the ability to continue this impactful research in the United States, the petitioner retained the North America Immigration Law Group (NAILG) to file his National Interest Waiver (NIW) petition. NAILG emphasized how his work not only addresses urgent healthcare needs but also supports innovation in therapeutic design, clinical decision-making, and healthcare cost efficiency.The petition was approved, formally recognizing his contributions as being of substantial merit and national importance to the United States.